Publication | Open Access

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

OncologyNintedanib Versus DocetaxelLume-lung 1Metronomic TherapyClinical TrialsBronchial NeoplasmPharmacotherapyCancer TreatmentMedicineRadiation OncologyLung CancerPhase 3Health Sciences